Research programme: skin disorder therapies - Evotec SE/Leo Pharma
Latest Information Update: 28 Jan 2023
At a glance
- Originator Evotec AG; LEO Pharma
- Developer Evotec SE; LEO Pharma
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for research development in Skin-disorders in Denmark
- 28 Jan 2023 No recent reports of development identified for research development in Skin-disorders in Germany
- 04 Dec 2018 Evotec and Leo Pharma enter into an agreement to discover and develop skin disorder therapies